Navigation Links
IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
Date:1/22/2013

ered into a license agreement with QUANTEL Medical that gives QUANTEL access to IRIDEX' MicroPulse technology, a further step towards making Fovea-friendly therapies using MicroPulse a new standard of care.

The Company also completed a tender offer in which it purchased 487,500 shares of its common stock at a purchase price of $4.10 per share during the fourth quarter. Total shares outstanding following the share buyback are estimated to be 8.5 million. Mr. Moore commented, "We were pleased with the success of the tender offer. It is one of the ways that we can achieve our goal of delivering shareholder value. We intend to continue to assess this option going forward and have $1 million in funds approved under our stock repurchase program yet to be utilized."

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's anticipated operating and financial results for the fiscal year 2012 fourth quarter and year end, t
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
2. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
3. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
4. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
5. IRIDEX Reports 2012 Third Quarter Results
6. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
7. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
8. IRIDEX Reports 2012 Second Quarter Results
9. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
10. IRIDEX Reports 2012 First Quarter Results
11. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
(Date:7/30/2015)...   Gaumard® Scientific Company today announced ... first operating system to support an entire family ... Gaumard users. UNI® version 2.27.21.0 adds enhanced functionality ... as well as improvements to laboratory functions, patient ... as EtCO 2 .  First ...
(Date:7/30/2015)... -- Global ENT (Ear, Nose, And ... 23.01 million in 2022, according to a new study ... population, increasing prevalence of ear, nose, and throat related ... target customer base are expected serve this market as ... to estimates published by the WHO, 15% of adult ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
... /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: ... of Western healthcare products and services in the ... (Group) Co., Ltd. ("Fosun Pharma"), a leading manufacturer ... devices in China, today announced the formation of ...
... 27, 2010 K-V Pharmaceutical Company (NYSE: KVa/KVb) today announced ... ended March 31, 2010 with the Securities and Exchange Commission. ... filing its delayed fiscal 2010 Form 10-K to enable its ... The Company is currently working on preparing and ...
Cached Medicine Technology:Chindex and Fosun Pharma Form Joint Venture 2Chindex and Fosun Pharma Form Joint Venture 3Chindex and Fosun Pharma Form Joint Venture 4Chindex and Fosun Pharma Form Joint Venture 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... New research ... Click here to read more on the Surviving Mesothelioma website. , ... Hospital in Missouri reviewed more than 12,000 cases of mesothelioma occurring between 1990 and ...
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial ... birds from the AC units and ventilation systems on hospital roofs. Bird droppings can ... Nile virus. When these droppings dry, the fine powder can be carried into hospitals ...
(Date:7/30/2015)... ... July 30, 2015 , ... Author Dr. Raul Llanos seeks to ... his new self-help book, “ Consciously Healing our Webs of Health, Wellbeing, Success, and ... “If we take responsibility for ourselves, we can create better realities.” His book illustrates ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After conducting ... , St. John’s Episcopal Hospital in Far Rockaway, N.Y., has hired Gerard ... , With more than 25 years of healthcare leadership experience, Walsh is an expert ...
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial ... implant, more commonly known as the “bionic eye,” researchers have determined the trial to ... tool for patients facing or already affected by complete vision loss as a result ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... Diagnostics, Holding Promise for Melanoma Patients, NEW ... International Melanoma Congress signals new promise,and hope in treating ... for,those in the advanced stages. Caught early, melanoma is ... melanoma is one of the most incurable,and deadly., ...
... 25 Fire evacuation from the comfort of,your home to ... of a,stadium is difficult for anyone. But it,s harder on ... living. Senior Beth Price was overcome with confusion when ... at 2:00 am on Tuesday morning. "We,didn,t get much notice, ...
... Assist in California Fires Response Effort, TALLAHASSEE, Fla., ... to the California wildfires, the Capital Area Chapter of,the ... the effort. "Whether across the country or around ... is prepared to respond to tragedy and in this,case, ...
... The 2007 Southern California,wildfires have disrupted the lives ... tremendous impact on a person emotionally and physically,including ... have,had to evacuate immediately, leaving behind their homes, ... ever be the same. Aside to,evacuees being affected, ...
... help prevent Alzheimer disease , Alzheimer disease (AD), ... of dementia, is characterized by the formation in the ... indicates that some drugs used to treat high blood ... AD. In a new study, in which they screened ...
... air a way out, experts say , THURSDAY, ... treat emphysema patients shows promise, researchers say. , ... (COPD), is a progressive, irreversible lung disease characterized ... are limited. , The new strategy, called airway ...
Cached Medicine News:Health News:Genes Unlock New Treatments for Deadly Melanoma 2Health News:St. Paul's Senior Homes & Services Welcomes Some of San Diego's Neediest Displaced Seniors 2Health News:St. Paul's Senior Homes & Services Welcomes Some of San Diego's Neediest Displaced Seniors 3Health News:Capital Area Chapter Deploys Volunteers to California 2Health News:California Association of Marriage & Family Therapists Offers Tips on How to Cope With a Traumatic Event 2Health News:JCI table of contents: Oct. 25, 2007 2Health News:JCI table of contents: Oct. 25, 2007 3Health News:JCI table of contents: Oct. 25, 2007 4Health News:JCI table of contents: Oct. 25, 2007 5Health News:JCI table of contents: Oct. 25, 2007 6Health News:JCI table of contents: Oct. 25, 2007 7Health News:JCI table of contents: Oct. 25, 2007 8Health News:JCI table of contents: Oct. 25, 2007 9
... The Elite II features ... proven University of Glasgow,(UG) algorithm. ... criteria to age, the UG,algorithm ... clinically,significant criteria: gender, age, race, ...
... face provides three contrast levels (high, 9.5 % ... 20/100. This test is designed to detect very ... contact lens evaluation or due to refractive surgery. ... the same contrast and acuity levels as the ...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
Medicine Products: